EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.
Location: United Kingdom, England, London
Employees: 11-50
Total raised: $195M
Founded date: 2021
Investors 4
| Date | Name | Website |
| 27.02.2022 | Jeito Capi... | jeito.life |
| 10.03.2024 | Omega Fund... | omegafunds... |
| 07.09.2022 | MRL Ventur... | mrlv.com |
| 28.05.2024 | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.11.2023 | - | $130M | - |
| 23.02.2022 | Series A | $65M | Jeito Capi... |
Mentions in press and media 11
| Date | Title | Description |
| 25.07.2024 | The AI Chip Race: A New Era of Semiconductor Dominance** ** | ** The semiconductor industry is experiencing a seismic shift. Artificial Intelligence (AI) is the driving force behind this transformation. Companies like SK Hynix are riding the wave, posting record profits as demand for AI chips skyrocke... |
| 24.07.2024 | Midyear Forecast: Top Trends To Watch In H2 2024 — From Chips To AI Funds | 5 Shares Email Facebook Twitter LinkedIn So far, 2024 has proceeded very much like 2023 in the startup world. AI is still the dominating talk of venture capital, funding is slightly up but most seem unsure if that’s a trend or a passing mom... |
| 29.05.2024 | Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion | - |
| 14.11.2023 | EyeBio Expands Series A to $130M | EyeBiotech, a London, UK-based clinical-stage ophthalmology biotechnology company, raised additional $65M in Series A funding. The round, which brought the total amount to $130M, saw participation form Bain Capital Life Sciences, Omega Fund... |
| 14.11.2023 | EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases | EyeBio doubles the size of its original Series A raise with an additional $65 million, with new investors Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joining the round to support accelerated development of its innovative ... |
| 14.06.2023 | EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret™ in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema | AMARONE (Anti-permeability Mechanism and Age-Related Ocular Neovascularization Evaluation) is first clinical trial of EyeBio’s lead asset Restoret, a Wnt agonist, in two retinal diseases of permeability |
| 06.03.2023 | EyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team | Additions to EyeBio’s leadership team include world-class disrupters with deep experience addressing urgent unmet needs in treatment of eye diseases |
| 22.02.2022 | EyeBiotech Raises $65M in Series A Funding | EyeBiotech Limited, a London, UK-based held ophthalmology biotechnology company, raised $65M in Series A funding. The round was led by SV Health Investors with participation from Samsara BioCapital, Jeito Capital, and MRL Ventures. The comp... |
| 22.02.2022 | Biotech startup EyeBio closes $65M to develop a new generation of eye disease therapies to protect, restore, and improve vision | It’s the 21st century, and there are still millions of people suffering from some forms of eye disorders. According to the Centers for Diseases and Control Prevention (CDC), approximately 12 million people 40 years and over in the United St... |
| 22.02.2022 | EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies | Leaders in ophthalmology drug development launch new global company to build and advance diversified portfolio of ocular therapies |
Show more